Some evidence for a comparable differential effect on breast cancer outcome for aromatase inhibitor therapy can be derived from subgroup analyses of five randomised controlled trials, in which the PR status and/or MammaPrint score were considered.7 This evidence concerns the gene CYP19A1 and breast cancer.